Ivabradine - A selective and specific If inhibitor: Efficacy and safety in stable angina

European Heart Journal, Supplement

Volumn 5, Issue G, 2003, Pages

  Fox, Kim ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Exercise tolerance test; Heart rate; Ischaemia; Ivabradine; ST segment depression; Stable angina

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IVABRADINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE TOLERANCE; FEMALE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; VISUAL DISORDER;

EID: 0141951905     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90006-X     Document Type: Article

References (41)

1. Staniforth AP. Contemporary management of chronic stable angina. Drugs Aging 2001; 18: 109-21.
2. Heidenreich PA, McDonald KM, Hastie T et al. An evaluation of beta-blockers, calcium antagonists, nitrates and alternative therapies for stable angina. Evidence Report/technology Assessment Number 10. AHRQ Publication No 00-E003. November 1999.
3. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature 1986; 324: 470-3.
4. f) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 1991; 434: 23-40.
5. Irisawa H, Brown HF, Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev 1993; 73: 197-227.
6. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996; 118: 1051-57.
7. Thollon C, Cambarrat C, Vian J et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994; 112: 37-42.
8. Gardiner SM, Kemp PA, March JE, Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol 1995; 115: 579-86.
9. Simon L, Ghaleh B, Puybasset L, Giudicelli J-F, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-66.
10. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998; 64: 192-203.
11. Borer JS, Fox K, Jaillon P, Lerebours G; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003; 107: 817-23.
12. Fujiura Y, Adachi H, Tsuruta M, Jacobs DR Jr, Hirai Y, Imaizumi T. Heart rate and mortality in a Japanese general population: an 18-year follow-up study. J Clin Epidemiol 2001; 54: 495-500.
13. Kristal-Boneh E, Silber H, Harari G, Froom P. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2000; 21: 116-24.
14. Palatini P, Julius S. Relevance of heart rate as a risk factor in hypertension. Curr Hypertens Rep 1999; 1: 219-24.
15. Seccareccia F, Pannozzo F, Dima F et al. for the Malattie Cardiovascolari Aterosclerotiche Istituto Superiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001; 91: 1258-63.
16. Bel A, Perrault LP, Faris B, Mouas C, Vilaine J-P, Menasche P. Inhibition of the pacemaker current: a bradycardic therapy for off-pump coronary operations. Ann Thorac Surg 1998; 66: 148-52.
17. Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol 1987; 59: 26F-32F.
18. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol 1988; 61: 1219-22.
19. Kaneko A, Tachibana M. A voltage-clamp analysis of membrane currents in solitary bipolar cells dissociated from Carassius aureus. J Physiol 1985; 358: 131-52.
20. Demontis GC, Longoni B, Barcaro U, Cervetto L. Properties and functional roles of hyperpolarization-gated currents in guinea-pig retinal rods. J Physiol 1999; 515: 813-28.
21. (h)) in retinal rod photoreceptors. Neuropharmacology 2000; 39: 1284-91.
22. Fihn SD, Williams SV, Daley J, Gibbons RJ, American College of Cardiology, American Heart Association, American College of Physicians-American Society of Internal Medicine. Guidelines for the management of patients with chronic stable angina: treatment. Ann Intern Med 2001; 135: 616-32.
23. Garratt KN. Stable angina pectoris. Curr Treat Options Cardiovasc Med 2000; 2: 161-72.
24. Gibbons RJ, Chatterjee K, Daley J et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of patients with Chronic Stable Angina). Circulation 1999; 99: 2829-48.
25. Task Force of the European Society of Cardiology. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394-413.
26. Bucher HC, Hengstler P, Schindler D et al. Percutaneous transluminal angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ 2000; 321: 73-7.
27. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9F.
28. Lechat P. Beta-blocker treatment in heart failure. Role of heart rate reduction. Basic Res Cardiol 1998; 93(suppl 1): 148-55.
29. Berdeaux A, Drieu La Rochelle C, Richard V, Giudicelli JF. Opposed responses of large and small coronary arteries to propranolol during exercise in dogs. Am J Physiol 1991; 261: H265-70.
30. Bortone AS, Hess OM, Gaglione A et al. Effect of propranolol on coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. Circulation 1990; 81: 1225-35.
31. Pepine CJ, Abrams J, Marks RG, Morris JJ, Scheidt SS, Handberg E. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol 1994; 74: 226-31.
32. Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf 1993; 4: 272-9.
33. Boskabady MH, Snashall PD. Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta-blockade in asthma. Respirology 2000; 5: 111-8.
34. Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade. Cardiovasc Drugs Ther 1991; 4(suppl 6): 1229-32.
35. Ramahi TM. Beta blocker therapy for chronic heart failure. Am Fam Physician 2000; 62: 2267-74.
36. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988; 116: 1729-34.
37. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-7.
38. Skarfors ET, Lithell HO, Selinus I, Aberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989; 298: 1147-52.
39. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind crossover study in hypertensive patients. Blood Press 1992; 1: 92-101.
40. Hakamaki T, Lehtonen A. Metabolic effects of spirapril and atenolol: results from a randomized, long-term study. Int J Clin Pharmacol Ther 1997; 35: 227-30.
41. Reneland R, Alvarez E, Andersson PE, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000; 14: 175-80.